January 7, 2025 08:00 AM EST
Pharma
Marketing

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

Nicole DeFeudis

Editor

John­son & John­son said its re­cent­ly ap­proved Ry­bre­vant and Laz­cluze com­bi­na­tion ther­a­py topped Tagris­so on over­all sur­vival in a Phase 3 tri­al, notch­ing a key …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA sets an ef­fi­ca­cy thresh­old for fu­ture weight loss drugs

Sanofi part­ners with Al­loy Ther­a­peu­tics to make new CNS drug

Cal­i­co, De­nal­i's ALS drugs miss pri­ma­ry ob­jec­tives in bas­ket study

Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Met­sera’s long-act­ing GLP-1 looks com­pet­i­tive in Phase 2 obe­si­ty study

A service from the Financial Times